MHRA response to EU exit no-deal legislative proposals consultation

7 January 2019

Following the outcome of the EU referendum, the Medicines and Healthcare products Regulatory Agency (MHRA) says it is working closely with the government to analyze the best options and opportunities available for the safe and effective regulation of medicines and medical devices in the UK.

Noting that the UK is leaving the European Union on March 29, 2019, it states: “We remain focused on delivering the deal that we have negotiated with the EU. However, as a responsible government, it is right that we continue to prepare for all scenarios and provide information so that other organisations can do the same.

Following its consultation on how medicines, medical devices and clinical trials would be regulated in a no-deal scenario, the MHRA has issued updated guidance setting out the UK’s proposed arrangements for regulation post March 29 with no deal.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK